Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ASRT
stocks logo

ASRT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
6.20M
-80.74%
-0.207
+88.64%
14.70M
-44.52%
-0.070
-50%
28.40M
-2.81%
-0.025
-85.29%
Estimates Revision
The market is revising Upward the revenue expectations for Assertio Holdings, Inc. (ASRT) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by -1.72%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-13.51%
In Past 3 Month
Stock Price
Go Down
down Image
-1.72%
In Past 3 Month
Wall Street analysts forecast ASRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASRT is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ASRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASRT is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.784
sliders
Low
3.00
Averages
3.00
High
3.00
Current: 0.784
sliders
Low
3.00
Averages
3.00
High
3.00
H.C. Wainwright
Buy
downgrade
$3
2025-08-12
Reason
H.C. Wainwright
Price Target
$3
2025-08-12
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Assertio to $3 from $3.50 and keeps a Buy rating on the shares. The company reported a sales beat and earnings miss, the analyst tells investors in a research note.
Alliance Global Partners
Buy
maintain
2025-05-13
Reason
Alliance Global Partners
Price Target
2025-05-13
maintain
Buy
Reason
Alliance Global Partners lowered the firm's price target on Assertio to $1.50 from $1.75 and keeps a Buy rating on the shares following the Q1 report. The company's Q1 revenue was below forecast driven largely by Rolvedon, the analyst tells investors in a research note. Now that Assertio appears to have cleaned up the opioid overhang litigation, the share price should start tracking Rolvedon, for better or worse, contends Alliance Global .
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$4 → $3.5
2025-03-19
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$4 → $3.5
2025-03-19
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$4
2024-12-16
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$4
2024-12-16
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Assertio Holdings Inc (ASRT.O) is -2.39, compared to its 5-year average forward P/E of 7.74. For a more detailed relative valuation and DCF analysis to assess Assertio Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
7.74
Current PE
-2.39
Overvalued PE
92.57
Undervalued PE
-77.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.20
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.35
Undervalued EV/EBITDA
0.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.95
Current PS
0.00
Overvalued PS
1.38
Undervalued PS
0.53
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ASRT News & Events

Events Timeline

(ET)
2025-11-10
16:26:03
Assertio Appoints Paul Schwichtenberg as President and COO
select
2025-11-10
16:25:37
Assertio Revises FY25 Product Sales Forecast to $110M-$112M, Down from $108M-$118M
select
2025-11-10
16:24:52
Assertio Announces Q3 EPS of 11 Cents Compared to (3 Cents) Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-11NASDAQ.COM
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports

  • Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.

  • KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.

  • Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.

  • Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.

[object Object]
Preview
9.5
11-11NASDAQ.COM
Assertio (ASRT) Exceeds Q3 Earnings and Revenue Projections

  • Earnings Performance: Assertio (ASRT) reported quarterly earnings of $0.11 per share, exceeding expectations of a loss of $0.08 per share, marking a significant earnings surprise of +237.50%.

  • Revenue Growth: The company generated revenues of $49.46 million for the quarter, surpassing the Zacks Consensus Estimate by 83.86% and showing a year-over-year increase from $29.2 million.

  • Stock Outlook: Assertio shares have declined by 12.7% year-to-date, underperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Industry Context: The Medical - Drugs industry, to which Assertio belongs, ranks in the top 37% of Zacks industries, suggesting that industry performance could significantly influence Assertio's stock movement in the future.

[object Object]
Preview
9.5
11-11SeekingAlpha
Assertio Shares Climb Following Revenue Surprise

  • Quarterly Revenue Growth: Assertio (ASRT) reported a 69.4% increase in third quarter revenue, reaching $49.46M, exceeding analysts' expectations by $22.44M, driven by strong demand and significant orders for Rolvedon.

  • Stock Performance: Following the revenue report, Assertio's stock rose approximately 7% in after-hours trading.

  • Revised Financial Forecast: The company adjusted its full-year net product sales forecast to $110M to $112M, down from $108M to $118M, and updated its adjusted EBITDA forecast to $14M to $16M.

  • Leadership Change: Assertio promoted Paul Schwichtenberg to the newly created position of President and Chief Operating Officer.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Assertio Holdings Inc (ASRT) stock price today?

The current price of ASRT is 0.7841 USD — it has increased 0.51 % in the last trading day.

arrow icon

What is Assertio Holdings Inc (ASRT)'s business?

Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

arrow icon

What is the price predicton of ASRT Stock?

Wall Street analysts forecast ASRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASRT is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Assertio Holdings Inc (ASRT)'s revenue for the last quarter?

Assertio Holdings Inc revenue for the last quarter amounts to 49.46M USD, increased 69.36 % YoY.

arrow icon

What is Assertio Holdings Inc (ASRT)'s earnings per share (EPS) for the last quarter?

Assertio Holdings Inc. EPS for the last quarter amounts to 0.11 USD, decreased -466.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Assertio Holdings Inc (ASRT)'s fundamentals?

The market is revising Upward the revenue expectations for Assertio Holdings, Inc. (ASRT) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by -1.72%.
arrow icon

How many employees does Assertio Holdings Inc (ASRT). have?

Assertio Holdings Inc (ASRT) has 58 emplpoyees as of December 05 2025.

arrow icon

What is Assertio Holdings Inc (ASRT) market cap?

Today ASRT has the market capitalization of 75.35M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free